Top stories this morning from the Proactive Investors UK newsroom.
Avacta Group PLC (LON:AVCT) has said it will go to clinic “well ahead of original plans” with a drug candidate that combines its binding protein technology with chemotherapy. The group's tumour microenvironment activated drug conjugates (TMAC) are a ground-breaking new form of cancer immunotherapy.
Argo Blockchain PLC (LON:ARB) has reported “significantly better” trading conditions since early May and has raised expectations for its second quarter on the back of improving prices in the cryptocurrency market. The crypto mining services group said in a trading update that its results for May were “materially ahead” of internal budgets, reflecting an improvement in market conditions as well as the earlier than expected delivery of crypto mining hardware.
WideCells (LON:WDC) says its Iconic Labs new media business has agreed a deal and begun work on a consulting and marketing services engagement with a UK based financial services business. The relationship’s on a long-term retainer basis, with initial revenues over the first year expected to exceed £1 million.
Benchmark Holdings PLC (LON:BMK) said it expects its full-year results to meet market estimates after delivering a 23% rise in adjusted earnings (EBITDA) in the first half. The aquaculture health, nutrition and genetics firm posted adjusted EBITDA of £7.5mln for the first half on revenue of £78.3mln, up 3.4% on a year ago.